Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Receives Delisting Warning from Nasdaq, Has Until March 15 to Regain Compliance

NEW YORK, Sept. 20 (GenomeWeb News) - Sequenom has received a warning letter from Nasdaq's listing qualifications department because the company's shares do not comply with Nasdaq's $1 minimum bid price requirement, Sequenom said today.

 

As GenomeWeb News reported last week, the company failed to keep the closing price of its shares at or above $1 for 30 consecutive business days.

 

Sequenom now has 180 days, or until March 15, 2006, to regain compliance by closing at or above $1 per share for at least 10 consecutive business days. If the company does not regain compliance by this deadline, its common stock will be delisted.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.